Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, covers the month of July 2026. The report was issued on July 1, 2026, from London, UK, to comply with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding total voting rights.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 4,316,276,428 Ordinary Shares of 31½ pence each as of June 30, 2026.
- Treasury Shares: 270,881,064 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,045,395,364.
Material Changes
The filing text does not provide a clear value for material changes in financial performance or operations compared to prior periods. The document serves as a notification of the current share capital and voting rights count rather than a performance update.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The only operational note is that the total voting rights figure may be used by shareholders to determine notification requirements under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,045,395,364) against internal records for compliance with FCA disclosure thresholds.
- Confirm the count of Treasury Shares (270,881,064) to ensure accurate calculation of outstanding shares.
- Check the issued share capital total (4,316,276,428) for consistency with the latest annual report (Form 20-F).
- Note that this filing contains no financial performance data; refer to quarterly or annual reports for revenue and profit metrics.